Profile data is unavailable for this security.
About the company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
- Revenue in CHF (TTM)61.52bn
- Net income in CHF12.88bn
- Incorporated1966
- Employees112.77k
- LocationRoche Holding AGGrenzacherstrasse 124BASEL 4002SwitzerlandCHE
- Phone+41 616881111
- Websitehttps://www.roche.com/
Mergers & acquisitions
| Acquired company | ROG:SWX since announced | Transaction value |
|---|---|---|
| 89bio Inc | 34.79% | 3.19bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | 22.29bn | 6.21bn | 144.19bn | 17.60k | 23.57 | 8.75 | 17.30 | 6.47 | 6.43 | 6.43 | 23.05 | 17.34 | 0.5146 | 3.39 | 6.01 | 1,652,671.00 | 14.35 | 5.26 | 18.18 | 6.38 | 78.72 | 78.47 | 27.88 | 12.54 | 1.31 | 18.69 | 0.5376 | 108.47 | 6.04 | 5.08 | -91.53 | -38.34 | -8.71 | 4.10 |
| Amgen Inc | 28.16bn | 5.91bn | 155.06bn | 28.00k | 26.40 | 23.40 | 19.35 | 5.51 | 14.23 | 14.23 | 67.84 | 16.06 | 0.4029 | 1.48 | 4.49 | -- | 8.45 | 7.90 | 11.52 | 10.18 | 73.30 | 74.68 | 20.98 | 20.55 | 0.8958 | 18.59 | 0.8631 | 72.99 | 9.95 | 7.65 | 88.53 | 1.20 | 25.03 | 8.27 |
| Merck & Co Inc | 49.81bn | 13.99bn | 223.74bn | 75.00k | 16.17 | -- | 15.62 | 4.49 | 7.28 | 7.28 | 25.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 78.55 | 75.41 | 28.09 | 21.08 | -- | 22.68 | -- | -- | 1.31 | 9.38 | 6.64 | 32.21 | -- | 6.01 |
| AstraZeneca plc | 44.55bn | 7.20bn | 224.65bn | 94.30k | 31.40 | 6.39 | 19.72 | 5.04 | 4.40 | 4.40 | 27.19 | 21.62 | 0.5299 | 1.72 | 4.43 | 450,259.30 | 8.57 | 4.32 | 11.81 | 5.95 | 81.90 | 80.22 | 16.18 | 9.39 | 0.6856 | 10.39 | 0.4152 | 107.68 | 18.03 | 17.27 | 18.14 | 39.43 | 13.27 | 1.20 |
| Novartis | 43.14bn | 10.71bn | 250.71bn | 75.88k | 21.65 | 6.45 | 17.49 | 5.81 | 5.48 | 5.48 | 22.10 | 18.41 | 0.5284 | 2.27 | 6.89 | -- | 13.10 | 11.11 | 17.82 | 14.89 | 75.82 | 74.78 | 24.79 | 26.20 | 0.8868 | 16.89 | 0.4318 | 62.30 | 8.91 | 2.45 | 17.11 | 11.62 | 8.57 | 6.62 |
| Roche Holding AG | 61.52bn | 12.88bn | 287.30bn | 112.77k | 22.06 | 8.33 | 16.72 | 4.67 | 16.04 | 16.04 | 76.61 | 42.49 | 0.6076 | 2.15 | 5.40 | 545,480.30 | 13.63 | 13.69 | 19.85 | 21.13 | 73.62 | 72.22 | 22.43 | 20.80 | 1.12 | 16.42 | 0.4551 | 65.69 | 1.69 | 1.07 | 55.61 | -2.06 | 3.50 | 1.49 |
| AbbVie Inc | 45.70bn | 1.80bn | 302.33bn | 55.00k | 168.46 | -- | 36.67 | 6.62 | 1.33 | 1.33 | 33.68 | -1.49 | 0.4302 | 3.66 | 4.92 | 1,084,436.00 | 1.73 | 5.44 | 2.46 | 7.09 | 71.16 | 68.89 | 4.02 | 13.73 | 0.5992 | 7.60 | 1.04 | 134.96 | 3.71 | 11.11 | -12.07 | -11.58 | 12.03 | 8.00 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 07 Jan 2026 | 28.00m | 3.99% |
| UBS Asset Management Switzerland AGas of 06 Jan 2026 | 27.43m | 3.90% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 17.98m | 2.56% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 15.13m | 2.15% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2025 | 10.60m | 1.51% |
| Geode Capital Management LLCas of 05 Feb 2026 | 8.92m | 1.27% |
| BlackRock Advisors (UK) Ltd.as of 09 Jan 2026 | 7.43m | 1.06% |
| BlackRock Asset Management Deutschland AGas of 09 Jan 2026 | 6.01m | 0.86% |
| Pictet Asset Management SAas of 08 Jan 2026 | 4.98m | 0.71% |
| FIL Investments Internationalas of 09 Jan 2026 | 4.90m | 0.70% |
